Monoclonal antibodies are one of the new medical approaches for effective and efficient treatment of various diseases. These types of antibodies are homogeneous molecules that recognize only one type of epitope. One of the types of monoclonal antibodies is Perginulumab (MAb17-1A), under the brand name Panorex, which is derived from a mouse antibody that is expressed on epithelial tissue and various carcinomas. Also, in this research, vascular endothelial growth factor A (VEGF-A) was used, which is one of the most important factors of angiogenesis and can be targeted as an efficient biomarker as an antigen for the treatment of colorectal cancer. The aim of this research is to design a monoclonal antibody called gancilumab to evaluate its anti-tumor effects for colorectal cancer. Therefore, the identification code of antigen and antibody was removed from NCBI bioinformatics databases and saved in PDB format, then the antibody was engineered and its affinity with antigen was checked with sift, interprosorf, Phyer2, sabpred and HADDOCK2.2 software. Considering the appropriate features of the Edrecolomab monoclonal antibody in the treatment and prevention of colorectal cancer and the demand for improving the performance of the antibody, including increasing its high affinity and affinity by producing variants resulting from targeted mutagenesis in its variable part, it can be Antibody was used as a good candidate in the diagnosis and treatment of colorectal cancer.

Edrecolomab, monoclonal antibody, VEGF-A, colorectal cancer